Multiple Agency Fiscal Note Summary

Bill Number: 1422 S HB Title: Drug take-back program

Estimated Cash Receipts

Agency Name	2025-27		2027-29			2029-31			
	GF-State	NGF-Outlook	Total	GF-State	NGF-Outlook	Total	GF-State	NGF-Outlook	Total
Office of State	Non-zero but	indeterminate cos	t and/or savings	. Please see disc	ussion.				
Treasurer			_						
Department of	0	0	1,036,000	0	0	1,036,000	0	0	1,036,000
Health									
Total \$	0	0	1,036,000	0	0	1,036,000	0	0	1,036,000

Agency Name	2025	5-27	2027	-29	2029-	-31
	GF- State	Total	GF- State	Total	GF- State	Total
Local Gov. Courts						
Loc School dist-SPI						
Local Gov. Other	No fiscal impac	t				
Local Gov. Total						

Estimated Operating Expenditures

Agency Name			2025-27			2027-29				2029-31			
	FTEs	GF-State	NGF-Outlook	Total	FTEs	GF-State	NGF-Outlook	Total	FTEs	GF-State	NGF-Outlook	Total	
Office of State Treasurer	.0	0	0	0	.0	0	0	0	.0	0	0	0	
Department of Health	.0	0	0	0	.0	0	0	0	.0	0	0	0	
Total \$	0.0	0	0	0	0.0	0	0	0	0.0	0	0	0	

Agency Name		2025-27			2027-29			2029-31		
	FTEs	GF-State	Total	FTEs	GF-State	Total	FTEs	GF-State	Total	
Local Gov. Courts										
Loc School dist-SPI										
Local Gov. Other	No fis	cal impact								
Local Gov. Total										

Estimated Capital Budget Expenditures

Agency Name		2025-27			2027-29			2029-31		
	FTEs	Bonds	Total	FTEs	Bonds	Total	FTEs	Bonds	Total	
Office of State Treasurer	.0	0	0	.0	0	0	.0	0	0	
Department of Health	.0	0	0	.0	0	0	.0	0	0	
Total \$	0.0	0	0	0.0	0	0	0.0	0	0	

Agency Name	cy Name 2025-27				2027-29		2029-31		
	FTEs	GF-State	Total	FTEs	GF-State	Total	FTEs	GF-State	Total
Local Gov. Courts									
Loc School dist-SPI									
Local Gov. Other	No fis	cal impact							
Local Gov. Total	1								

Estimated Capital Budget Breakout

NONE

Prepared by: Amy Hatfield, OFM	Phone:	Date Published:
	(360) 280-7584	Final 2/27/2025

Individual State Agency Fiscal Note

Bill Number: 1422 S HB	Title: Drug take-back program	Agency:	090-Office of State Treasurer
Part I: Estimates			
No Fiscal Impact			
Estimated Cash Receipts to:			
Non-zer	o but indeterminate cost and/or savings.	Please see discussion.	
Estimated Operating Expenditure NONE	es from:		
Estimated Capital Budget Impact:	:		
NONE			
The cash receipts and expenditure e and alternate ranges (if appropriate	stimates on this page represent the most likely fi c), are explained in Part II.	iscal impact. Factors impacting to	he precision of these estimates,
Check applicable boxes and follo	w corresponding instructions:		
If fiscal impact is greater than form Parts I-V.	n \$50,000 per fiscal year in the current bien	nium or in subsequent biennia	, complete entire fiscal note
X If fiscal impact is less than \$2	50,000 per fiscal year in the current bienniu	ım or in subsequent biennia, co	omplete this page only (Part I)
Capital budget impact, comp	lete Part IV.		
Requires new rule making, c	omplete Part V.		
Legislative Contact:		Phone:	Date: 02/20/2025
Agency Preparation: Dan Mas	on	Phone: (360) 902-8990	Date: 02/20/2025
Agency Approval: Dan Mas	on	Phone: (360) 902-8990	Date: 02/20/2025
OFM Review: Megan T	udor	Phone: (360) 890-1722	Date: 02/26/2025

Part II: Narrative Explanation

II. A - Brief Description Of What The Measure Does That Has Fiscal Impact

Significant provisions of the bill and any related workload or policy assumptions that have revenue or expenditure impact on the responding agency by section number.

SHB 1422 modifies the drug take-back program by modifying fee and enforcement regulations and addressing program operator performance.

Under section 3, fees collected must be deposited in the secure drug take-back program account. The general fund is the recipient of the earnings from investments under RCW 43.84.092(4).

There will be some de-minimis work for OST which can be completed within current practices and resources.

II. B - Cash receipts Impact

Cash receipts impact of the legislation on the responding agency with the cash receipts provisions identified by section number and when appropriate, the detail of the revenue sources. Description of the factual basis of the assumptions and the method by which the cash receipts impact is derived. Explanation of how workload assumptions translate into estimates. Distinguished between one time and ongoing functions.

Projected cash flows are currently unavailable; therefore, estimated earnings from investments are indeterminable.

There may be an impact on the debt service limitation calculation. Changes to the earnings credited to the general fund impacts, by an equal amount, general state revenues.

II. C - Expenditures

Agency expenditures necessary to implement this legislation (or savings resulting from this legislation), with the provisions of the legislation that result in the expenditures (or savings) identified by section number. Description of the factual basis of the assumptions and the method by which the expenditure impact is derived. Explanation of how workload assumptions translate into cost estimates. Distinguished between one time and ongoing functions.

Part III: Expenditure Detail

III. A - Operating Budget Expenditures

NONE

III. B - Expenditures by Object Or Purpose

NONE

III. C - Operating FTE Detail: FTEs listed by classification and corresponding annual compensation. Totals agree with total FTEs in Part I and Part IIIA.

NONE

III. D - Expenditures By Program (optional)

NONE

Part IV: Capital Budget Impact

IV. A - Capital Budget Expenditures
NONE

IV. B - Expenditures by Object Or Purpose

NONE

IV. C - Capital Budget Breakout

Acquisition and construction costs not reflected elsewhere on the fiscal note and description of potential financing methods.

NONE

IV. D - Capital FTE Detail: FTEs listed by classification and corresponding annual compensation. Totals agree with total FTEs in Part IVB.

NONE

Part V: New Rule Making Required

Provisions of the bill that require the agency to adopt new administrative rules or repeal/revise existing rules.

Individual State Agency Fiscal Note

Bill Number: 1422 S HB	Title: Dr	Title: Drug take-back program Agency: 303-Department of H							
Part I: Estimates				•					
No Fiscal Impact									
Estimated Cash Receipts to:									
ACCOUNT		FY 2026	FY 2027	2025-27	2027-29	2029-31			
Secure Drug Take-back Program Account-State 22u-1		518,000	518,000	1,036,000	1,036,000	1,036,000			
	Total \$	518,000	518,000	1,036,000	1,036,000	1,036,000			
Estimated Operating Expenditure NONE Estimated Capital Budget Impact									
NONE									
NONE									
The cash receipts and expenditure e			ost likely fiscal impa	ct. Factors impactir	ng the precision of th	hese estimates,			
and alternate ranges (if appropriate Check applicable boxes and follo	•								
If fiscal impact is greater than	=	_	rent hiennium or i	n subsequent bien	nia complete enti	re fiscal note			
form Parts I-V.	1 \$30,000 pc1	nscar year in the eur	Tent blemmam of t	iii suosequent olen	ша, сопірісте спи	re fiscal flote			
If fiscal impact is less than \$	50,000 per fisc	cal year in the currer	nt biennium or in s	subsequent biennia	a, complete this pa	ge only (Part I			
Capital budget impact, comp	lete Part IV.								
Requires new rule making, c	omplete Part V	7.							
Legislative Contact:			Pho	ne:	Date: 02/2	0/2025			
Agency Preparation: Donna C	ompton			ne: 360-236-4538	Date: 02/2				
Agency Approval: Kristin B				ne: 3607911657	Date: 02/2				
OFM Review: Amy Hat				ne: (360) 280-7584					

Part II: Narrative Explanation

II. A - Brief Description Of What The Measure Does That Has Fiscal Impact

Significant provisions of the bill and any related workload or policy assumptions that have revenue or expenditure impact on the responding agency by section number.

The fiscal impact has not changed from the previous fiscal note provided for house bill 1422. This substitute bill removes the requirement that collection goals for the next year must meet or exceed the reporting years collection goals and the requirement to report to the Department of Health (department) if the estimated budget for the next year is less than 80% of the prior budget periods. This substitute removes the ability to initiate enforcement action if revisions submitted by the program operator do not comply with the applicable law or the program's operator's department-approved plan and removes the additional authority for the department to assess civil fines and suspend, restrict or impose reasonable conditions on a program operator's drug-take back program as established in house bill 1422.

This legislation amends RCW 69.48.100 (Annual Program Report) to add additional reporting components, and amends RCW 69.48.120 (Department to Set Program Fees) to remove restrictions that limit the department's program operation fee to ten percent of the program's annual expenditures as reported to the department.

The department expects the amendment to RCW 69.48.120 (Department to Set Program Fees) to increase cash receipts to align with historical levels, which would allow the department to set fees at a level sufficient to recover the costs associated with administration, oversight, and enforcement of this program.

The department does not expect this legislation to increase expenditures.

II. B - Cash receipts Impact

Cash receipts impact of the legislation on the responding agency with the cash receipts provisions identified by section number and when appropriate, the detail of the revenue sources. Description of the factual basis of the assumptions and the method by which the cash receipts impact is derived. Explanation of how workload assumptions translate into estimates. Distinguished between one time and ongoing functions.

Under current statute, the department collects a fee to support administrative, oversight, and enforcement costs for the drug take-back program in accordance with RCW 69.48.120 (Department to set program fees). The department shall not impose any fees in excess of its actual administrative, oversight, and enforcement costs and may not exceed ten percent of the program operator's annual expenditures as reported to the department. The department supports two program operators and bases the fee off the lowest annual operation costs.

The department assumes spending for the program operator with the lowest annual operating costs to remain around 1,110,000, therefore restricting revenue to \$222,000 per year. The department assumes that expenditure authority for the Safe Medication Return Program Account to remain at \$740,000 per fiscal year.

The projected revenue increase is the disparity between the current projected revenue and the department's expenditure authority for this fund.

Net change in revenue to the department:

FY 2026: \$518,000 FY 2027: \$518,000 FY 2028: \$518,000 FY 2029: \$518,000

II. C - Expenditures

Agency expenditures necessary to implement this legislation (or savings resulting from this legislation), with the provisions of the legislation that result in the expenditures (or savings) identified by section number. Description of the factual basis of the assumptions and the method by which the expenditure impact is derived. Explanation of how workload assumptions translate into cost estimates. Distinguished between one time and ongoing functions.

Part III: Expenditure Detail

III. A - Operating Budget Expenditures

NONE

III. B - Expenditures by Object Or Purpose

NONE

III. C - Operating FTE Detail: FTEs listed by classification and corresponding annual compensation. Totals agree with total FTEs in Part I and Part IIIA.

NONE

III. D - Expenditures By Program (optional)

NONE

Part IV: Capital Budget Impact

IV. A - Capital Budget Expenditures

NONE

IV. B - Expenditures by Object Or Purpose

NONE

IV. C - Capital Budget Breakout

Acquisition and construction costs not reflected elsewhere on the fiscal note and description of potential financing methods.

NONE

IV. D - Capital FTE Detail: FTEs listed by classification and corresponding annual compensation. Totals agree with total FTEs in Part IVB.

NONE

Part V: New Rule Making Required

Provisions of the bill that require the agency to adopt new administrative rules or repeal/revise existing rules.

LOCAL GOVERNMENT FISCAL NOTE

Department of Commerce

Bill Number:	1422 S HB	Title:	Drug take-back program					
Part I: Juri	art I: Jurisdiction-Location, type or status of political subdivision defines range of fiscal impacts.							
Legislation I	mpacts:							
Cities:								
Counties:								
Special Distr	ricts:							
Specific juris	sdictions only:							
Variance occ	urs due to:							
Part II: Es	timates							
X No fiscal im	pacts.							
Expenditure	s represent one-time	costs:						
Legislation 1	provides local option	:						
Key variable	es cannot be estimate	d with certai	anty at this time:					
Estimated reve	nue impacts to:							
None								
Estimated expe	enditure impacts to:							
None								

Part III: Preparation and Approval

Fiscal Note Analyst: Alice Zillah	Phone: 360-725-5035	Date: 02/24/2025
Leg. Committee Contact:	Phone:	Date: 02/20/2025
Agency Approval: Allan Johnson	Phone: 360-725-5033	Date: 02/24/2025
OFM Review: Amy Hatfield	Phone: (360) 280-7584	Date: 02/25/2025

Page 1 of 2 Bill Number: 1422 S HB

FNS060 Local Government Fiscal Note

Part IV: Analysis

A. SUMMARY OF BILL

Description of the bill with an emphasis on how it impacts local government.

CHANGES BETWEEN THIS VERSION AND PRIOR VERSION OF THE BILL:

The changes made in the substitute version do not create fiscal impacts for local governments.

SUMMARY OF THE BILL:

The legislation modifies the reporting requirements, penalty schedule, and other elements of oversight of the drug take-back program managed by the Department of Health.

B. SUMMARY OF EXPENDITURE IMPACTS

Expenditure impacts of the legislation on local governments with the expenditure provisions identified by section number and when appropriate, the detail of expenditures. Delineated between city, county and special district impacts.

The legislation would have no expenditure impacts for local governments. Prosecutors and court-appointed defense attorneys would not be involved in adjudication processes for the civil fines created by the bill.

C. SUMMARY OF REVENUE IMPACTS

Revenue impacts of the legislation on local governments, with the revenue provisions identified by section number, and when appropriate, the detail of revenue sources. Delineated between city, county and special district impacts.

The legislation would have no revenue impacts for local governments.

Please note that court impacts, including judicial costs, clerk costs, and court fees are described in fiscal notes prepared by the Administrative Office of the Courts. Local government fiscal notes include city and county expenditures for law enforcement investigations and arrests, indigent defenders, prosecutors, and jail costs.

Page 2 of 2 Bill Number: 1422 S HB



Multiple Agency Ten-Year Analysis Summary

Bill Number	Title
1422 S HB	Drug take-back program

This ten-year analysis is limited to the estimated cash receipts associated with the proposed tax or fee increases.

Estimated Cash Receipts

	Fiscal Year 2026	Fiscal Year 2027	Fiscal Year 2028	Fiscal Year 2029	Fiscal Year 2030	Fiscal Year 2031	Fiscal Year 2032	Fiscal Year 2033	Fiscal Year 2034	Fiscal Year 2035	2026-35 TOTAL
Office of State Treasurer	0	0	0	0	0	0	0	0	0	0	0
Department of Health	518,000	518,000	518,000	518,000	518,000	518,000	518,000	518,000	518,000	518,000	5,180,000
Total	518,000	518,000	518,000	518,000	518,000	518,000	518,000	518,000	518,000	518,000	5,180,000



Ten-Year Analysis

Bill Number	Title	Agency				
1422 S HB	Drug take-back program	090 Office of State Treasurer				
This ten-year analysis is limited to agency ten-year projection can be found at http://	y estimated cash receipts associated with the proposed tax or fee increas www.ofm.wa.gov/tax/default.asp .	es. The Office of Financial Management				

Estimates

X No Cash Receipts			Partially I	ndetermi	nate Cas	h Receip	Indeterminate Cash Receipts					
Name of Tax or Fee	Acct Code											

Agency Preparation: Dan Mason	Phone: (360) 902-8990	Date: 2/20/2025 4:59:56 pm
Agency Approval: Dan Mason	Phone: (360) 902-8990	Date: 2/20/2025 4:59:56 pm
OFM Review:	Phone:	Date:



Ten-Year Analysis

Bill Number	Title	Agency
1422 S HB	Drug take-back program	303 Department of Health

This ten-year analysis is limited to agency estimated cash receipts associated with the proposed tax or fee increases. The Office of Financial Management ten-year projection can be found at http://www.ofm.wa.gov/tax/default.asp.

+	ates
	12146
_эш	

No Cash Receipts		Partially Indeterminate Cash Receipts		Indeterminate Cash Receipts
------------------	--	---------------------------------------	--	-----------------------------

Estimated Cash Receipts

Name of Tax or Fee	Acct Code	Fiscal Year 2026	Fiscal Year 2027	Fiscal Year 2028	Fiscal Year 2029	Fiscal Year 2030	Fiscal Year 2031	Fiscal Year 2032	Fiscal Year 2033	Fiscal Year 2034	Fiscal Year 2035	2026-35 TOTAL
Drug-take back program	22U	518,000	518,000	518,000	518,000	518,000	518,000	518,000	518,000	518,000	518,000	5,180,000
Total		518,000	518,000	518,000	518,000	518,000	518,000	518,000	518,000	518,000	518,000	5,180,000

Biennial Totals 1.036.000 1.036.000 1.036.000 1.036.000 1.036.000 5.180.000

Narrative Explanation (Required for Indeterminate Cash Receipts)

Under current statute, the department collects a fee to support administrative, oversight, and enforcement costs for the drug take-back program in accordance with RCW 69.48.120 (Department to set program fees). The department shall not impose any fees in excess of its actual administrative, oversight, and enforcement costs and may exceed ten percent of the program operator's annual expenditures as reported to the department. The department supports two program operators and bases the fee off lowest annual operation costs.

The department assumes spending for the program operator with the lowest annual operating costs to remain around 1,110,000, therefore restricting revenue to \$222,000 year. The department assumes that expenditure authority for the Safe Medication Return Program Account to remain at \$740,000 per fiscal year.

The projected revenue increase is the disparity between the current projected revenue and the department's expenditure authority for this fund.

Net change in revenue to the department:

FY 2026: \$518,000 FY 2027: \$518,000 FY 2028: \$518,000 FY 2029: \$518,000



Ten-Year Analysis

Bill Number	Title	Agency
1422 S HB	Drug take-back program	303 Department of Health

Agency Preparation: Donna Compton	Phone:	360-236-4538	Date:	2/21/2025	8:52:13 am
Agency Approval: Kristin Bettridge	Phone:	3607911657	Date:	2/21/2025	8:52:13 am
OFM Review:	Phone:		Date:		